Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OCRELIZUMAB Cause Wrong technique in product usage process? 35 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 35 reports of Wrong technique in product usage process have been filed in association with OCRELIZUMAB (OCREVUS). This represents 0.1% of all adverse event reports for OCRELIZUMAB.

35
Reports of Wrong technique in product usage process with OCRELIZUMAB
0.1%
of all OCRELIZUMAB reports
0
Deaths
2
Hospitalizations

How Dangerous Is Wrong technique in product usage process From OCRELIZUMAB?

Of the 35 reports, 2 (5.7%) required hospitalization.

Is Wrong technique in product usage process Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OCRELIZUMAB. However, 35 reports have been filed with the FAERS database.

What Other Side Effects Does OCRELIZUMAB Cause?

Covid-19 (11,454) Fatigue (5,704) Urinary tract infection (3,618) Headache (3,036) Multiple sclerosis (2,609) Asthenia (2,509) Nasopharyngitis (2,479) Gait disturbance (2,384) Pneumonia (2,333) Pain (2,327)

What Other Drugs Cause Wrong technique in product usage process?

EVOLOCUMAB (21,664) ALBUTEROL (17,114) ADALIMUMAB (11,766) PEGFILGRASTIM (10,217) ETANERCEPT (9,835) ERENUMAB-AOOE (9,359) SACUBITRIL\VALSARTAN (8,022) LEUPROLIDE (5,062) FENTANYL (2,812) SEMAGLUTIDE (2,538)

Which OCRELIZUMAB Alternatives Have Lower Wrong technique in product usage process Risk?

OCRELIZUMAB vs OCRIPLASMIN OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE OCRELIZUMAB vs OCTREOTIDE OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE

Related Pages

OCRELIZUMAB Full Profile All Wrong technique in product usage process Reports All Drugs Causing Wrong technique in product usage process OCRELIZUMAB Demographics